Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway

Carcinogenesis

Volumn 35, Issue 8, 2014, Pages

  Hui, Chang ^a   Xiaoli, Peng ^b   Qian, Bai ^a   Yong, Zhou ^a   Xiaoping, Yu ^b   Qianyong, Zhang ^a   Jundong, Zhu ^a,b   Mantian, Mi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; AMPELOPSIN; ANTINEOPLASTIC AGENT; INITIATION FACTOR 4B; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLNITROSOUREA; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER GROWTH; CELL LYSATE; CELL SURVIVAL; CELL VIABILITY ASSAY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84905686841     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu118     Document Type: Article

References (38)

1. Youlden,D.R. et al. (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol., 36, 237-248.
2. National Cancer Institute (NCI), U.S. Department of Health and Human Services: The NCI Strategic Plan for Leading the Nation to Eliminate the Suffering and Death Due to Cancer. Bethesda, MD: NCI; 2006.
3. Pola,C. et al. (2013) Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells. Cancer Res., 73, 4571-4578.
4. Nagalingam,A. et al.(2012) Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res., 14, R35.
5. Martinelli,E. et al.(2013) Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer., 133, 2089-2101.
6. Dobbin,Z.C. et al.(2013) The Importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci., 14, 8213-8227.
7. Zhang,D.M. et al.(2013) Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis., 34, 1331-1342.
8. Lau,M.T. et al.(2013) Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One., 8, e59083.
9. Gridelli,C. et al.(2008) The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist., 13, 139-147.
10. Manne,N.D. et al.(2013) Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse. Int J Oncol., 42, 2134-2140.
11. Perez,J. et al. (2012) Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. PLoS One., 7, e32458.
12. Wang,X. et al.(2013) Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis. Carcinogenesis., 34, 1323-1330.
13. Hildebrandt,M.A. et al.(2012) Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res., 18, 3705-3713.
14. Zhou,H.Y. et al.(2012) Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer., 31, 8-18.
15. Lionello,M. et al.(2012) High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study. J Oral Pathol Med., 41, 136-140.
16. Zou,Z. et al.(2012) Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy., 8, 1798-1810.
17. De,P. et al.(2013) Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope. Cancer Treat Rev., 39, 403-412.
18. Zhang,X. et al.(2013) Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer. Curr Cancer Drug Targets., 13, 175-187.
19. Hui,C. et al.(2013) Flavonoids, flavonoid subclasses and breast cancer risk: a meta-analysis of epidemiologic studies. PLoS One., 8, e54318.
20. Song,J.K. et al.(2013) Citrus fruit intake and breast cancer risk: a quantitative systematic review. J Breast Cancer., 16, 72-76.
21. Yadegarynia,S. et al.(2012) Profiling flavonoid cytotoxicity in human breast cancer cell lines: determination of structure-function relationships. Nat Prod Commun., 7, 1295-1304.
22. Hui,C. et al.(2010) Anticancer activities of an anthocyanin-rich extract from black rice against breast cancer cells in vitro and in vivo. Nutr Cancer., 62, 1128-1136.
23. Zhang,B. et al.(2012) Ampelopsin sodium exhibits antitumor effects against bladder carcinoma in orthotopic xenograft models. Anticancer Drugs., 23, 590-596.
24. Qi,S. et al.(2012) Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways. Int Immunopharmacol., 12, 278-287.
25. Ni,F. et al.(2012) Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice. PLoS One., 7, e38802.
26. Nkrumah-Elie,Y.M. et al.(2012) Diallyl trisulfide as an inhibitor of benzo(a)pyrene-induced precancerous carcinogenesis in MCF-10A cells. Food Chem Toxicol., 50, 2524-2530.
27. Steward,W.P. et al.(2013) Cancer chemoprevention: a rapidly evolving field. Br J Cancer., 109, 1-7.
28. Cazzaniga,M. et al.(2012) Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol., 985620.
29. Chumsri,S. et al.(2014) mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. Future Oncol., 10, 443-456.
30. Zhang,H. et al.(2014) Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res., 16, R36.
31. Arnedos,M. et al.(2014) Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol., 25, 605-610.
32. Pathiraja,T.N. et al.(2014) Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer. Sci Transl Med., 6, 229ra41.
33. Fox,E.M. et al.(2013) Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res., 15, R55.
34. Miller,T.W. et al.(2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest., 120, 2406-2413.
35. Massarweh,S. et al.(2014) A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat., 143, 325-332.
36. LoRusso,P.M. (2013) Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology., 84, 43-56.
37. Radhakrishnan,P. et al.(2013) Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers. Cancer Res., 73, 1118-1127.
38. Jeong,E.H. et al.(2012) Dual Inhibition of PI3K/Akt/mTOR pathway and role of autophagy in non-small cell lung cancer cells. Tuberc Respir Dis (Seoul)., 72, 343-351.